title: Correlation between cancer location and oncological outcome after radical prostatectomy.
abstract: OBJECTIVE
  To examine the association between cancer location, resection margins and oncological outcome in patients undergoing radical prostatectomy.
  
  
  METHODS
  A total of 505 patients who underwent radical prostatectomy between 1993 and 2009 were included in this analysis. Cancer location, resection margins and pathological factors were assessed based on the 2010 General Rules for Clinical and Pathological Studies on Prostate Cancer. Biochemical recurrence was defined as prostate-specific antigen >0.2 ng/mL.
  
  
  RESULTS
  Positive resection margins were found in 38.4% of all cases, in 30.3% of pT2 cases and in 57.7% of pT3 cases. The cancer was distributed evenly among the apex-anterior, apex-posterior and middle lesions, which each accounted for approximately 30% of the whole lesion in the main tumor. A higher rate of positive resection margins (47.6%) was found in the apex-anterior lesions. In minor tumors, most cancer was located in the middle lesion and accounted for approximately 60% of the lesion. However, positive resection margins were detected significantly more frequently in the apex-anterior lesion of minor tumors. The 5-year and 10-year biochemical recurrence-free survival rates were 36.2% and 32.0%, respectively, in patients with a positive resection margin, and 82.7% and 77.4%, respectively, in those with a negative resection margin. Cancer location was an independent risk factor for biochemical recurrence and a positive resection margin. Recurrence-free survival was lower in pT2 cases with a positive resection margin compared with pT3 cases with a negative resection margin.
  
  
  CONCLUSIONS
  Cancer location and occurrence of positive resection margins can have negative effects on recurrence-free survival. Thus, it is of utmost importance to avoid positive resection margins during radical prostatectomy.
authors.affiliation: Department of Urology, Section of Cancer Prevention & Epidemiology, Clinical Research Center, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan. khashine@shikoku-cc.go.jp
authors.forename: Katsuyoshi
authors.initials: K
authors.lastname: Hashine
authors.forename: Yoshiteru
authors.initials: Y
authors.lastname: Ueno
authors.forename: Kensuke
authors.initials: K
authors.lastname: Shinomori
authors.forename: Iku
authors.initials: I
authors.lastname: Ninomiya
authors.forename: Norihiro
authors.initials: N
authors.lastname: Teramoto
authors.forename: Natsumi
authors.initials: N
authors.lastname: Yamashita
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000453:epidemiology / Q000209:etiology / Q000473:pathology; D009367:Neoplasm Staging; D011183:Postoperative Complications / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy / Q000009:adverse effects / Q000379:methods; D011471:Prostatic Neoplasms / Q000097:blood / Q000401:mortality / Q000473:pathology / Q000601:surgery; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D017430:Prostate-Specific Antigen